Table 5.
Variables | Number (n=389)a |
2-year OS p-valueb |
2-year OS HR(95% CI) b |
5-year OS p-valueb |
5-year OS HR(95% CI) b |
Overall survival p-valueb |
Overall survival HR(95% CI) b |
---|---|---|---|---|---|---|---|
p53/AFP | |||||||
+/high | 113 | 0.222 | 0.298 | 0.343 | |||
-/low | 92 | 0.438 | 0.812(0.480-1.374) | 0.203 | 0.750(0.481-1.169) | 0.248 | 0.777(0.506-1.192) |
+/low | 122 | 0.038 | 0.584(0.352-0.969) | 0.110 | 0.724(0.487-1.075) | 0.249 | 0.804(0.554-1.165) |
-/high | 62 | 0.345 | 0.760(0.429-1.345) | 0.147 | 0.693(0.423-1.137) | 0.097 | 0.668(0.415-1.075) |
p21/AFP | |||||||
+/high | 52 | 0.504 | 0.701 | 0.859 | |||
-/low | 164 | 0.294 | 0.734(0.411-1.309) | 0.524 | 0.857(0.534-1.376) | 0.833 | 0.952(0.604-1.501) |
+/low | 50 | 0.530 | 0.790(0.378-1.650) | 0.463 | 0.803(0.446-1.444) | 0.902 | 1.034(0.603-1.774) |
-/high | 123 | 0.958 | 1.015(0.575-1.794) | 0.911 | 1.028(0.638-1.656) | 0.635 | 1.118(0.706-1.770) |
nm23/AFP | |||||||
+/high | 159 | 0.424 | 0.647 | 0.883 | |||
-/low | 23 | 0.373 | 0.581(0.176-1.917) | 0.917 | 0.962(0.466-1.986) | 0.908 | 1.040(0.535-2.023) |
+/low | 191 | 0.205 | 0.769(0.513-1.154) | 0.271 | 0.827(0.590-1.160) | 0.536 | 0.903(0.655-1.246) |
-/high | 16 | 0.600 | 1.258(0.533-2.971) | 0.708 | 1.145(0.563-2.330) | 0.770 | 1.106(0.563-2.171) |
VEGF/AFP | |||||||
+/high | 137 | 0.100 | 0.197 | 0.130 | |||
-/low | 55 | 0.027 | 0.444(0.217-0.910) | 0.133 | 0.672(0.400-1.129) | 0.291 | 0.778(0.489-1.239) |
+/low | 38 | 0.164 | 0.605(0.298-1.228) | 0.094 | 0.598(0.328-1.092) | 0.026 | 0.518(0.291-0.923) |
-/high | 159 | 0.201 | 0.756(0.493-1.161) | 0.155 | 0.772(0.540-1.103) | 0.182 | 0.792(0.562-1.115) |
Notes: a information regarding AFP level was unavailable for 30 patients (n=389); HR, hazard ratio; CI, confidence interval. b Adjusted for drinking status, BCLC stages, PVTT ,radical hepatic resection and adjuvant antiviral treatment. OS, overall survival; HR, hazard ratio; CI, confidence interval; NA, not available.